SequelSEC

VivoSim Labs, INC. VIVS

Biological Products, (No Diagnostic Substances) · CIK 0001497253 · Fiscal year ends 0331

AnnualQuarterlyTTM
Revenue
$18.00K
Fiscal year ended 2026-06-30
Operating income
-$2.76M
Fiscal year ended 2026-06-30
Free cash flow
-$3.24M
Fiscal year ended 2026-06-30

VivoSim Labs, INC. (VIVS) reported revenue of $18.00K and net income of -$1.34M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from VivoSim Labs, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

VivoSim Labs, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$18.00K$40.00K$26.00K$28.00K$37.00K$51.00K$24.00K$30.00K$39.00K$29.00K
Cost of revenueUnavailable$0$0$0$0$0$2.00K$1.00K$2.00KUnavailable
Gross profitUnavailable$40.00K$26.00K$28.00KUnavailable$51.00K$22.00K$29.00K$37.00KUnavailable
Operating income-$2.76M-$3.19M-$2.75M-$2.64M-$2.92M-$3.15M-$3.47M-$2.61M-$3.39M-$3.10M
Net income-$1.34M-$5.76M-$2.69M-$2.54M-$2.84M$6.85M-$3.45M-$2.55M-$3.34M-$3.04M
Research & development$1.13M$1.12M$1.14M$923.00K$1.00M$859.00K$1.78M$984.00K$1.40M$1.06M
Weighted-average diluted sharesshares 5.24MUnavailableshares 2.61Mshares 2.60Mshares 2.50MUnavailableshares 1.50Mshares 1.50Mshares 1.22MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$3.00K$0$0$2.00K$0$0$0$0$2.00K$0
Diluted EPS$-0.25Unavailable$-1.03$-0.98$-1.14Unavailable$-2.28$-1.68$-2.74Unavailable
Selling, general & administrative$1.64M$2.10M$1.64M$1.74M$1.95M$2.35M$1.71M$1.65M$2.02M$2.06M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

VivoSim Labs, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$1.67M$5.02M$4.29M$6.68M$9.06M$11.31M$1.16M$3.17M$6.19M$2.90M
Total assets$3.85M$7.39M$6.96M$9.69M$11.98M$14.65M$3.84M$6.75M$9.47M$6.35M
Current assets$3.23M$6.63M$6.04M$7.59M$9.68M$12.13M$2.10M$4.78M$7.28M$3.94M
Total liabilities$6.19M$8.48M$2.52M$2.62M$2.44M$4.16M$3.48M$3.07M$2.81M$2.75M
Current liabilities$1.89M$2.78M$2.48M$2.45M$2.14M$3.74M$2.94M$2.41M$2.03M$1.86M
Total equity incl. NCI-$2.35M-$1.10M$4.44M$7.06M$9.54M$10.49M$364.00K$3.68M$6.66M$3.60M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$640.00K$408.00K$297.00K
Accounts receivable$29.00K$32.00K$33.00K$32.00K$32.00K$30.00K$26.00K$29.00K$48.00K$33.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$621.00K$1.02M$671.00K$580.00K$673.00K$1.64M$930.00K$419.00K$1.12M$627.00K

Cash flow

VivoSim Labs, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$3.21M-$2.24M-$2.27M-$2.38M-$3.94M-$2.04M-$1.80M-$2.64M-$2.98M-$2.67M
Capital expenditures$23.00K$0$0$0$0$0$0$13.00K$0$0
Investing cash flow-$23.00K$94.00K$0$0$0$9.00M$4.00K$0$20.00K$13.00K
Financing cash flow-$118.00K$2.88M-$118.00K$0$1.68M$3.18M-$216.00K-$371.00K$6.25M$264.00K
Net change in cash-$3.35M$736.00K-$2.39M-$2.38M-$2.26M$10.15M-$2.01M-$3.01M$3.29M-$2.39M
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$40.00K$43.00K$52.00K$59.00K$61.00K$61.00K$67.00K$68.00K$70.00K$71.00K

Derived

VivoSim Labs, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$3.24M-$2.24M-$2.27M-$2.38M-$3.94M-$2.04M-$1.80M-$2.66MUnavailable-$2.67M
Gross marginUnavailable100.0%100.0%100.0%Unavailable100.0%91.7%96.7%94.9%Unavailable
Operating margin-15327.8%-7967.5%-10576.9%-9410.7%-7878.4%-6184.3%-14450.0%-8693.3%-8682.1%-10675.9%
FCF margin-17977.8%-5595.0%-8734.6%-8492.9%-10648.6%-3990.2%-7504.2%-8850.0%Unavailable-9210.3%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.70x2.38x2.44x3.10x4.52x3.25x0.72x1.98x3.58x2.12x
Revenue YoY growth-51.4%-21.6%8.3%-6.7%-5.1%75.9%380.0%Unavailable-48.0%-82.1%
Net margin-7433.3%-14410.0%-10350.0%-9089.3%-7683.8%13435.3%-14362.5%-8496.7%-8574.4%-10500.0%
R&D / revenue6288.9%2812.5%4384.6%3296.4%2705.4%1684.3%7416.7%3280.0%3594.9%3665.5%
CapEx / revenue127.8%0.0%0.0%0.0%0.0%0.0%0.0%43.3%Unavailable0.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VIVS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-K · Filed 2026-07-14View SEC filing
10-Q · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-K · Filed 2025-06-05View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.